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ABSTRACT 
Pathophysiology of premature ejaculation (PE) is very complex because it is associated with many 
factors, which can be grouped into biological factors and psychological factors. Various diseases have been 
found correlate between psychological factors and biological factors through cytokines, one of which is IFN-
g (IFN-). IFN- affect indolamine dioxygenase enzyme (IDO) and decrease levels of serotonin. Low levels of 
serotonin leads to PE. The purpose of this study was to prove the relationship of serotonin and IFN- in 
pathophysiology of PE. 
This study was designed as a pretest-posttest double-blind cross-over control group design. 
Patients with PE were divided into 2 groups: control group and treatment group. Treatment group received 
flouxetine 20 mg for 30 days. Then the control and treatment groups were crossed after passing a 14-days 
washout period. Previously as a control group to treatment group and received flouxetine 20 mg per day 
for 30 days. Before and after treatment in each group was examined the levels of serotonin and IFN-. 
Of the 26 subjects, each group there was 13 subjects. Flouxetine 20 mg per day for 30 days 
increased serotonin levels were significantly (p < 0.05), and decreased levels of IFN- were significantly (p < 
0.05). Increased levels of serotonin and decreased levels of IFN- was significantly associated with 
improvements (intravaginal ejaculatory latency time) ejaculation in PE patient. 
From these results it can be concluded that PE occurs because decreased levels of serotonin. 
Decreased levels of serotonin are associated with increased levels of IFN-. 
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INTRODUCTION 
Pathophysiology of PE is still an interesting 
subject to be investigated, because of the many 
factors involved in the phatophisyologies and the 
mechanism is very complex. These factors can be 
grouped into two factors: biological and psychological 
factors, but how the interrelated of these factors still 
need to do further research. In some disorders in 
addition to PE, it was found    the    relationship    
between    serotonin    and cytokines, one of which is 
IFN-. The problem is how these factors are 
interrelated in the pathophysiology of PE? 
Regarding the mechanism of ejaculation there 
were  consists  of  two  phases,  namely  emission   and 
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expulsion phases. In general it can be explained 
ejaculation occurs because the stimulus was triggered 
by a stimulus such as glan penis and tactile stimuli 
from various areas in the cerebral cortex. The 
disorders of ejaculation are PE, retrograde ejaculation, 
delayed ejaculation and an ejaculation.
1 
PE is the most common ejaculation disorders. 
Ejaculation occurs very rapidly, from the moment of 
penetration of penis into the vagina until ejaculation is 
very short, the inability to control ejaculation, and the 
distress in question, and spouse. The time required 
from the time of the penetration penis into the vagina 
until ejaculation is called intravaginal ejaculatory 
latency time (IELT). To measure the time specified in 
the study less than or equal to 2 minutes.
2-5 
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Serotonin is one of the neurotransmitter 
involved in ejaculation.
6 
The role of serotonin in the 
ejaculation can be explained by several studies that 
have been carried out. Research in this field using 
antidepressants, one of which is the Selective 
Serotonin Re-uptake Inhibitors (SSRIs). As research 
conducted by one researcher using one type of SSRI is 
flouxetine 20 mg. The result was flouxetine can fix PE. 
Flouxetine combined with tadafil can significantly 
prolong the intravaginal ejaculatory latency time (IELT) 
in patients with PE. Other studies also use flouxetine 
20 mg for 8 weeks, showed improvement ejaculate 
reaches 68%.
19
 With another type of SSRI paroxetine 
20 mg is the research done by measuring intravaginal 
ejaculatory latency time (IELT) was also found to 
provide improvements to PE, and found no side 
effects.
16 
Then recently with dapoxetine, which is one type 
of SSRI with short half life and rapid onset of action, so 
it can be given about 3 hours before sexual 
intercourse, have a very high concern. One of the 
studies regarding the efficacy and tolerability of 
dapoxetine in PE, involving 2614 patients found that 
dapoxetine may improve ejaculatory control and 
sexual enhancement and found no serious adverse 
events.
17,21 
Later research found a relationship of serotonin 
and cytokines in various types of disorders outside the 
PE. Serotonin activation likely contribute to 
inflammation in blood vessels during aterogenesis.
13
 
One of the cytokines interferon can lead to decreased 
levels of serotonin because interferon can increase 
serotonin re-uptake and interferon can decreased 
serotonin synthesis via the mechanism of indoleamine 
2,3-dioxygenase enzyme (IDO).
18,23
 Interferon can also 
cause decreased levels of tryptophan which are 
precursors of serotonin.
9 
Serotonin is derived from the amino acid 
tryptophan. Metabolism may be through two ways, 
namely: first through the IDO enzyme, which will 
transform tryptophan into kynurenin, and second 
through tryptophan hydroxylase enzymes, which will 
transform triptopan into serotonin. IDO enzyme can 
be activated by IFN-γ. In the event of increased levels 
of IFN-γ, the IDO enzyme will become more active so 
tryptophan be metabolized via the enzyme IDO 
becomes kynurenin, and the other is due to reduce of 
serotonin.
9,23 
From the description above and the research 
results can be formulated in several ways, among 
others, that serotonin is a neurotransmitter that plays 
a role in PE, low serotonin levels lead to reduced 
inhibition and ejaculation occur rapidly. There was a 
correlation of anxiety, IFN- and serotonin in patients 
with PE.
20
 That is why researchers want to know the 
correlation between IFN- and serotonin in 
pathophysiology of PE. In this study, flouxetine was 
applied to prove this hypothesis. 
 
METHODS 
In order to prove the hypothesis on the research 
carried out with experimental study design is double-
blind cross-over posttest pretest-control group design. 
Flouxetine used in this study, because of the difficulty 
to get dapoxetine. Subjects were randomly divided 
into 2 groups, one group will receive placebo 1 
capsule/day for 4 weeks (30 days), and one other 
group will receive flouxetine 20 mg/day for 4 weeks 
(30 days). Subjects were evaluated every 4 weeks. At 
the end of week 4 all subjects examined its 
ejaculation, serotonin levels, levels of IFN-g and 
anxiety. Then all the subjects experienced during the 
2-week washout. Once that was carried out cross 
(Cross over) against a group of research subjects. Who 
got the placebo group received flouxetine and vice 
versa. Examination performed on the first day when 
screening, day 30, day 45 and day 74. 
PE is checked through a structured interview 
based on the DSM IV criteria. Timing or intravaginal 
ejaculatory latency time (IELT) ≤ 2-minute interview 
conducted by examination carried out 4 times. First 
time start, both on day-30, the third on day 45, four 
on day 74. Severity measured by PE Severity Index 
(PESI). 
Examination anxiety was carried out using the 
Taylor Manifest Anxiety Scale (T- MAS). Examination 
was performed at baseline anxiety (h0), day-30, day-
to-45, and day-74. Examination of IFN-g (IFNγ) 
performed at the Prodia Laboratory Denpasar. Blood 
samples were collected from venous blood cubiti, this 
examination using ELISA method. Examination 
conducted at the Laboratory of blood serotonin Prodia 
Denpasar. Venous blood samples were taken from 
cubiti, for the storage of more than 6 hours can be 
done with a temperature of 2-8 degrees Celsius. To 
protect the serotonin made by the addition of 0.1% 
ascorbic acid solution. Examination conducted by the 
method of Ultra Sensitive Enzyme Immunoassay (EIA). 
 
RESULTS 
This study involved 26 of PE men patients aged 
less than 50 years. The patients are divided into 2 
(two) groups, namely the control and treatment 
groups, so that each numbered 13 people. After 30 
days followed by a 14-day washout phase, then was 
proceed with the examination of levels of serotonin 
and IFN-. Washout performed during 14 days.  
 
Serotonin 
Independent t-test analysis showed significance 
difference between control group and treatment 
group. Means of serotonin in treatment group was 
165.2871.35 and in control group was 195.2995.29. 
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Analysis of significance with independent t-test 
showed that the value t = 0.918 and p = 0.368. It 
means that the means levels of serotonin in the two 
groups did not differ (p > 0.05). 
Analysis of treatment effects were tested based 
on the means levels of serotonin between the groups 
after the treatment is given. The results of the analysis 
of significance with independent t-test showed that 
the means levels of serotonin in treatment group was 
205.03113.93 and the means of control group was 
102.5290.72. Significance analysis showed that the 
value t = 2.54 and p = 0.018. It means that the average 
levels of serotonin in the two groups differ 
significantly (p < 0.05). 
 
IFN- 
Comparability of test aims to compare the mean 
levels of IFN-. The results of the analysis of 
significance with independent t-test showed  mean  
treatment group was 0.962.71  and  the means levels 
of control group was 1.09  2.03. Analysis of 
significance with independent t-test showed that the 
value t = 0.14 and p = 0.889.  in both groups did not 
differ (p > 0.05). 
Analysis of treatment effects were tested with 
independent t-test showed that  mean of  treatment 
group was  0.15  0.09 and  the average levels of 
control group   was  0.33  0.17. Analysis of 
significance with independent t-test showed that the 
value t = 3.32 and p = 0.004.  in both groups were 
significantly different (p < 0.05). 
 
Period effects and residual effects 
After 30 days and then go into the second period. 
In the second period carried the cross, where the 
control group who had previously received treatment 
with placebo have given flouxetine 20 mg daily for 30 
days, whereas the treatment group receiving a 
placebo for 30 days as well. Between the first and 
second period there is a 14-day washout phase. To 
determine the effect of the first period of the second 
period and the period analyzed the effect of residual 
effects. 
 
Serotonin levels 
The analysis aims to determine the effects of 
period effects that arise related to cross-over design 
with two periods, namely the provision of treatment 
to compare the mean difference in change in 
serotonin levels of the first period to the period 
between the two treatment groups. The results of the 
analysis of significance with independent t-test 
showed that the mean difference in change in 
serotonin levels of the treated  47.86  140.13 the 
average control group was -76.07  195.28. Analysis of 
significance with independent t-test showed that the 
value t = 1.36 and p = 0.198. It means that the period 
effect serotonin levels in the two groups did not differ 
(p> 0.05). 
IFN-g (IFN- ) t-test showed that the mean levels 
of IFN-  in control group was 1.23 2.84, and mean 
levels in treatment group was -0.33 2.02. Analysis of 
significance with independent t-test showed that the 
value t = 1.18 and p = 0.261.  It means levels of IFN-g 
in both groups did not differ (p > 0.05). 
The analysis aims to determine the residual 
effects of residual effects of treatment are still 
relevant in the second period cross-over design 
comparing the mean changes in serotonin levels in the 
two periods between treatment groups. The results of 
the analysis of significance with independent t-test 
showed that the average change in serotonin levels of 
the treated group was -39.52  99.50  average control 
group was 52.8693.28.  Analysis of significance with 
independent t-test showed that the value t = 0.26 and 
p = 0.800. This means that the residual effects in both 
groups did not differ (p> 0.05). 
 
Effect of Flouxetine for Levels of IFN-g (IFNγ) and 
Serotonin Levels in PE 
To determine the effect of giving flouxetine to 
decrease levels of IFNγ and increase levels of 
serotonin and PE, tested by logistic regression test. 
Based on the analysis found that increased levels of 
serotonin have the greatest impact on improving PE 
with the odds ratio (OR) = 2.025 (95% CI: 1.006 to 
3.045) and p-value = 0.011. This suggests that elevated 
levels of serotonin have an influence on the 
improvement of PE were significantly (p <0.05) 
To determine the effect of giving flouxetine to 
improve PE was analysis using Chi-Square test is based 
on 2 x 2 cross table. Based on the analysis found that 
in the treated group of 8 people (61.54%) had 
improvement of PE and the remaining 38.46% is still 
suffering from PE, whereas in the control group there 
were only 2 people (15.38%) who experienced 
improvements in ejaculation 84.62% of early and still 
suffer from PE. With chi-square test found that there 
is a relationship between flouxetine with 
improvements in patients with PE  were significantly 
(p <0.05). 
 
DISCUSSION 
In this study it was found that the average age of 
patients with PE were in the range of 20-50 years.  
Analysis of significance with independent t-test 
showed that the probability of significance (p) for the 
age variable is p = 0.075. This means that the average 
age in both groups did not differ (p > 0.05).   This 
suggests that age is negligible effects on changes 
levels of IFN-  and levels of serotonin. The mean long-
married people with PE in this study were 6.62 ± 6.39; 
lowest 1-year and the longest 25 years (p = 0.075). The 
mean long-married in treatment group was 8.46 ± 
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8.10 and mean of the control group was 4.78 ± 3.47. 
No statistically significant influence (p = 0.145) for 
other factors. 
In the study conducted in Korea with 
questionnaire spread through the internet, with a 
lifespan of 20 years to 59 years found that there was 
no difference in the prevalence of PE in a particular 
age group.
22
 Thus it can be argued that long-married 
factors are negligible effects on IFN- and serotonin. 
Cholesterol and blood sugar factor in this study 
were also analyzed. It was found that total cholesterol 
levels averaged 191.08 ± 37.25 and blood sugar levels 
on average were 97.92 ± 10.12. Analysis of significance 
with independent t-test showed that the probability of 
significance (p) for blood sugar and total cholesterol, 
respectively p = 0, 490, and p = 0.208. It means that 
blood sugar and total cholesterol in both groups did 
not differ (p > 0.05). This suggests that these variables 
are negligible influence on changes in IFN- and 
serotonin levels. 
 
IFN- 
The results of the analysis of significance with 
independent t-test showed  that mean of  treatment 
group was 0.09  0.15, and average levels of control 
group was 0.17 0.33.  Analysis of significance with 
independent t-test showed that the value t = 3.32 and 
p = 0.004.  in both groups were significantly different 
(p<0.05). Based on the analysis of Spearman's 
correlation coefficient obtained between the levels of 
IFN-γ and improve of PE is r = 0.582 and p = 0.002 (p 
<0.05). 
IFN- has a negative correlation with serotonin. 
In this study found the correlation coefficient was r = -
0.718 with p = 0.001. It mean decrease levels of IFN-g 
significantly correlated with an increase levels of 
serotonin. IFN- can enhance IDO enzyme that causes 
a decrease levels of serotonin in several types of 
viruses and cancer who received interferon therapy. 
 
Levels of Serotonin in PE 
Serotonin had been studied and can be cited as 
the cause of PE. In the present study also found that 
about 61, 54% of patients with PE improved after 
being given flouxetine 20 mg/day for 30 days. Analysis 
of significance with independent t-test showed that 
the value t = 2.54 and p = 0.018. This means that the 
average levels of serotonin in the two groups differ 
significantly (p <0.05). Based on Spearman's 
correlation test, it was obtained that r = - 0.664 and p 
= 0.001. This suggests that elevated levels of serotonin 
associated with improvements in PE. 
The role of serotonin in PE has been widely 
studied. Such research is conducted using one type of 
SSRI is flouxetine 20 mg. The result was flouxetine can 
fix PE. Other studies also use flouxetine 20 mg for 8 
weeks, showed improvement ejaculate reaches 68%. 
Effect of Flouxetine for   IFN-, Serotonin and  
Improvement of PE 
Improvement of PE is related to elevated levels 
of serotonin (r = -0.664 and r = 0.001, decreased levels 
of IFN-g (r = 0.582 with p = 0.002). Flouxetine can 
significantly  decreased levels of IFN- for 4 weeks and  
improved of PE (r = 0.582 and p = 0.002). 
In this study it was found that the group given 
flouxetine 20 mg / day for 30 days, 8 out of 13 people 
(61.54%) improved its PE. With chi-square test found 
that there is a relationship between  flouxetine 20 
mg/day for 30 days with improvement in patients with 
PE were significantly (p <0.05). 
Other studies with flouxetine 20 mg for 8 weeks 
also provide improvements of about 68%. With 
another type of SSRI sertraline 50 mg during the first 
week has given approximately 68.75% improvement. 
With logistic regression test was found that 
increased levels of serotonin have the greatest impact 
on improving PE with the odds ratio (OR) = 2.025 (95% 
CI: 1.006 to 3.045). This suggests that increased levels 
of serotonin have the strongest influence on the 
improvement of PE were significantly (p <0.05). 
Side effects that occurred in this study only one 
person is decreased sex drive. Nevertheless need to 
get the attention and good explanations and 
understandable. Because some side effects found in 
the use of SSRIs are nausea, insomnia, somnolent, 
anxiety, sexual dysfunction and decreased sexual drive 
an orgasm. 
 
CONCLUSION 
Based on research results and the above 
discussion it can be concluded as follows 1) Flouxetine 
can decreased levels of IFNγ in patients with PE, 2) 
Flouxetine can increased serotonin levels in the blood 
of patients with PE; 3) Decreased levels of IFN-g (IFNγ), 
and increased levels of serotonin  associated with 
improvements of PE. 
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